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A B S T R A C T
Parasitic nematodes infect hundreds of millions of people and farmed livestock. Further, plant parasitic nema-
todes result in major crop damage. The pipeline of therapeutic compounds is limited and parasite resistance to
the existing anthelmintic compounds is a global threat. We have developed an INVertebrate Automated
Phenotyping Platform (INVAPP) for high-throughput, plate-based chemical screening, and an algorithm
(Paragon) which allows screening for compounds that have an eﬀect on motility and development of parasitic
worms. We have validated its utility by determining the eﬃcacy of a panel of known anthelmintics against
model and parasitic nematodes: Caenorhabditis elegans, Haemonchus contortus, Teladorsagia circumcincta, and
Trichuris muris. We then applied the system to screen the Pathogen Box chemical library in a blinded fashion and
identiﬁed compounds already known to have anthelmintic or anti-parasitic activity, including tolfenpyrad,
auranoﬁn, and mebendazole; and 14 compounds previously undescribed as anthelmintics, including benzox-
aborole and isoxazole chemotypes. This system oﬀers an eﬀective, high-throughput system for the discovery of
novel anthelmintics.
1. Introduction
Parasitic nematodes infect around one billion people, with the soil
transmitted nematodes Ascaris, hookworm and whipworm (Trichuris
trichiura) each aﬄicting hundreds of millions of people (Hotez, 2013).
These diseases cause high morbidity and are closely linked to poverty in
the developing world. The global impact of parasitic nematodes is
worsened by their eﬀect on livestock, equids and companion animals.
Parasitic nematodes of livestock are thought to cost approximately $10
billion annually with anthelmintic products comprising a major seg-
ment of the veterinary pharmaceuticals market (Roeber et al., 2013).
There are concerns that mass drug administration (MDA) programs
aimed at controlling or eradicating human parasitic nematodes will be
made unsustainable by anthelmintic resistance, jeopardising attempts
to eradicate these important tropical diseases (Prichard et al., 2012). In
the case of Trichuris, modelling indicates that existing benzimidazole
drugs are insuﬃciently eﬀective for single dose MDA programs de-
signed to break transmission; therefore eradication cannot be achieved
(Keiser and Utzinger, 2008; Levecke et al., 2014; Turner et al., 2016).
The current arsenal of veterinary anthelmintics is threatened by the
emergence and spread of resistance in parasitic nematodes of domes-
ticated animals, a recent example of which is the report of resistance to
monepantel in sheep nematode species only four years after introduc-
tion of the compound (Sales and Love, 2016; Scott et al., 2013). Multi-
class resistance is also common in parasitic nematodes of ruminants
(Rose et al., 2015; Sutherland, 2015) and equids (Matthews, 2014).
Thus, there is an urgent requirement for the identiﬁcation of novel
classes of anthelmintics.
Phenotypic screening is enjoying a resurgence in recent years and is
playing an increasingly important role in the modern drug discovery
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paradigm (Al-Ali, 2016). Furthermore, employment of this approach
using live nematodes ex vivo has been historically successful for target
identiﬁcation and lead optimisation. For example, a series of acetoni-
trile derivatives were identiﬁed using a Haemonchus contortus in vitro
larval development assay, and this led to the discovery of monepantel
(Kaminsky et al., 2008).
1.1. Automated systems for phenotypic screening of parasitic nematodes
and models of parasites
Given the need for new anthelmintics, there has been growing in-
terest both in phenotypic screens for identiﬁcation of new classes of
active small molecules and in systems for quantifying relevant readouts
of nematode viability such as growth and motility (Buckingham et al.,
2014; Buckingham and Sattelle, 2008). Manual scoring of motility,
growth or viability has been eﬀective and used to screen libraries of up
to 67,000 compounds (Burns et al., 2015; Tritten et al., 2011, 2012).
Automated systems oﬀer the potential of higher throughput and greater
reliability. Such approaches include indirect assessment of viability by
using the xCELLigence System; assessment of metabolic activity via
colorimetric assays such as resazurin, MTT, and acid phosphatase ac-
tivity; assessment of motor activity via isothermal microcalorimetry
and quantiﬁcation of movement-related light scattering (Nutting et al.,
2015; Silbereisen et al., 2011; Smout et al., 2010; Wangchuk et al.,
2016a, 2016b).
Imaging-based systems for quantiﬁcation of motility or growth have
also been developed. The “WormAssay” system quantiﬁes the motility
of macroscopic parasites such as Brugia malayi adult worms (Marcellino
et al., 2012). This system has been further developed into “The Wor-
minator”, which quantiﬁes smaller, microscopic nematode stages and
has been validated by quantifying the activity of several anthelmintics
(Storey et al., 2014). This system has a reported scan time of 30 s per
well, hence a throughput of around one and a quarter 6-well plates per
hour. A system based on single-well imaging and thresholding of motile
pixels with a throughput of around ﬁve 96-well plates per hour has
been reported (Preston et al., 2016a). Its utility has been demonstrated
by the successful screening of a 522-compound kinase inhibitor library
and the 400-compound Medicine for Malaria Venture Pathogen box on
Haemonchus contortus larvae (Preston et al., 2015, 2016b). A notable
recently-described screen of the eﬀects of 26,000 compounds on Cae-
norhabditis elegans growth/survival used WormScan, a system that uses
a conventional ﬂat-bed scanner to capture two frames of images of
whole plates and then uses an algorithm based on the diﬀerence image
to assign a value to each well that reﬂects motility/growth (Mathew
et al., 2012, 2016). This led to the identiﬁcation of several compounds
with previously unreported anthelmintic activity, including compounds
targeting PINK-1 and MEV-1. The authors reported a throughput of
approximately 25–40 96-well plates per hour.
1.2. Developing a new robust motility/growth quantiﬁcation system
focussed on rapid, high-throughput chemical screening
It is clear that recent developments in phenotypic screening of
parasitic and model nematodes have led to an acceleration of the dis-
covery of potential novel anthelmintic compounds. Given the large sizes
of drug-like compound libraries and the need to eﬃciently identify the
hit compounds therein that have the potential to be developed into
potent and selective anthelmintic lead molecules, it is desirable that
nematode phenotypic screening be further accelerated. Here, we pre-
sent the development of the INVAPP/Paragon system, which quantiﬁes
nematode motility/growth with a throughput of approximately 100 96-
well plates per hour, with a robust and unbiased approach. We validate
the system by quantifying the activity of a panel of known anthelmin-
tics on a variety of nematode species, and then by screening, in a
blinded fashion, the Medicines for Malaria Venture Pathogen Box for
compounds that block or reduce nematode growth.
2. Materials and methods
2.1. Ethics statement
All mouse experiments were approved by the University of
Manchester Animal Welfare and Ethical Review Board and performed
under the regulation of the United Kingdom Home Oﬃce Scientiﬁc
Procedures Act (1986) and the Home Oﬃce project licence 70/8127.
All ovine experiments were approved by the Moredun Research
Institute Experiments and Ethics Committee and performed under the
regulation of the United Kingdom Home Oﬃce Scientiﬁc Procedures
Act (1986) and the Home Oﬃce project licence 60/04421.
2.2. INVAPP/Paragon system
The INVAPP/Paragon system consists of a fast high-resolution
camera (Andor Neo, resolution 2560x2160, maximum frame rate 100
frames per second) with a line-scan lens (Pentax YF3528). Microtiter
plates are placed in a holder built into the cabinet and imaged from
below. Illumination is provided by an LED panel with acrylic diﬀuser.
Movies were captured using μManager (Edelstein et al., 2014). The
desirable movie frame length and duration of ﬁlming depends on the
particular organism under study and is speciﬁed below. Movies were
analysed using MATLAB scripts. Brieﬂy, movies were analysed by cal-
culating the variance through time for each pixel. The distribution of
these pixel variances was then considered, and pixels whose variance
was above the threshold (typically those greater than one standard
deviation away from the mean variance) were considered ‘motile’.
Motile pixels were assigned by well, by dividing the matrix evenly
across the width and height of the image, with plateColumns and pla-
teRows parameters used to specify the number of wells in the plate
image. The ‘motile’ pixels were then counted, generating a movement
score for each well. The source code for this software has been released
under the open source MIT license and is available at https://github.
com/fpartridge/invapp-paragon. A further MATLAB script has been
provided for batch processing of movies.
2.3. Caenorhabditis elegans motility and growth assays
C. elegans strains were maintained at 20 °C on nematode growth
medium agar seeded with the E. coli strain OP50. To obtain worms for
screening, a mixed-stage liquid culture was prepared by washing well-
fed worms from one small NGM plate into a medium of 50 ml S-com-
plete buﬀer with a pellet of approximately 2–3 g E. coli HB101. Cultures
were agitated at 200 rpm, 20 °C, until there were many adults present,
then synchronised at the L1 stage by bleaching. Fifty millilitre cultures
were pelleted and bleaching mix (1.5 ml 4M NaOH, 2.4 ml NaOCl,
2.1 ml water) added. Mixing for 4 min led to the release of embryos,
which were washed three times with 50 ml S-basal medium. The cul-
tures were incubated in 50 ml S-basal at 20 °C and agitated at 200 rpm
overnight to allow eggs to hatch and arrest as a synchronous L1 po-
pulation.
For the growth assay, C. elegans were cultured in a 96-well plate
format. Synchronised L1 were diluted to approximately 20 worms per
50 μl in S complete medium with around 1% w/v HB101 E. coli. Assay
plates were prepared with 49 μl of S-basal and 1 μl of DMSO or com-
pound in DMSO solution per well. Next, 50 μl of the L1 suspension were
added to each well. Final DMSO concentration was 1% v/v. Plates were
incubated at 20 °C before imaging using the INVAPP/Paragon system 5
days later. Prior to imaging, worm motion was stimulated mechanically
by inserting and removing a 96-well PCR plate into/from the wells of
the assay plate. Whole-plate 200 frame movies were recorded at 30
frames per second (7 s total).
For the adult motility assay, synchronised L1 were refed as a bulk
50 ml culture and cultured at 20 °C until they developed into young
adults. Worms were washed in S-basal and dispensed, approximately 20
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worms per well, into 96-well plates with compound dissolved in DMSO,
or DMSO alone and then incubated for 3 h. Final DMSO concentration
was 1% v/v. Whole-plate 200 frame movies were recorded at 30 frames
per second (7 s total).
For the anthelmintic panel screen using C. elegans in the acute
treatment adult motility assay and the growth assay, we screened n = 5
wells for each concentration, with each replicate concentration on
diﬀerent plates. Where the compound was active in the assay, we ﬁtted
a dose-response curve using 3-parameter log-logistic model and the R
package drc (Ritz and Streibig, 2005).
2.4. Trichuris muris motility assay
For the adult T. muris motility assay, male and female severe com-
bined immune deﬁciency mice (bred in the Biological Services Facility
at the University of Manchester) were infected with 200 embryonated
T. muris eggs in water by oral gavage. After 35 days, mice were killed
and their caecae and colons removed, opened longitudinally, and wa-
shed with pre-warmed Roswell Park Memorial Institute (RPMI) 1640
media supplemented with penicillin (500 U/ml) and streptomycin
(500 μg/ml). Adult T. muris worms were then removed using ﬁne for-
ceps and maintained in RPMI-1640/penicillin/streptomycin media at
approximately 37 °C and studied on the same day. Individual live
worms were placed into 96 well plates containing 75 μl of RPMI-1640/
penicillin/streptomycin medium plus 1% v/v ﬁnal concentration of
DMSO or compound dissolved in DMSO. Plates were incubated at 37 °C,
5% v/v CO2, and motility was analysed after 24 h. Whole plate 200
frame movies were recorded at 10 frames per second (20 s total).
2.5. Ovine parasitic nematode isolation
Six month-old, male Texel cross lambs that were raised under hel-
minth-free conditions were infected per os either with 15,000 T. cir-
cumcincta (isolate MTci2) larvae (L3) or 5000 H. contortus (isolate
MHco3) L3. Once a patent infection was detected by the observation of
nematodes eggs in faeces (around 21 days post-infection), the lambs
were ﬁtted with a collection harness and bag to enable faecal collection.
Pelleted faeces were collected from each bag 24 h later and placed in a
covered seed tray, which was incubated at room temperature (> 15 °C)
for 10 days before larval recovery using the modiﬁed Baermann tech-
nique (Manual of Veterinary Parasitological Laboratory Techniques,
1986). The next day L3 were recovered in ∼250 ml H2O, number es-
timation performed then the larvae were stored in 100 ml tap water in
75 cm2 surface area vented cap, suspension culture ﬂasks (Sarstedt Ltd
UK) at ∼ 5 °C for MTci2 and 8 °C for MHco3, respectively.
2.6. T. circumcincta assay
Ensheathed L3 T. circumcincta were used in this assay, which are the
infective form of the parasite that is ingested by the grazing host.
Approximately 30 worms were added to wells containing
compound + DMSO or DMSO alone (ﬁnal concentration 1% v/v).
Worms were incubated for 2 h in the dark at 25 °C. Movement was
stimulated by illuminating the plate with bright white light for 3 min
(Zeiss HAL100), before acquiring movies on the INVAPP/Paragon
system (200 frames, 10 frames per second).
2.7. H. contortus assay
H. contortus exsheathed L3 (xL3) were prepared by treatment with
sodium hypochlorite. A 1 ml solution containing around 1000 H. con-
tortus L3 was placed in a 35 mm petri dish. 20 μl sodium hypochlorite
solution (Fisher, S/5040/PC17) was added and incubated at room
temperature for 4 min. Exsheathment was monitored using a dissecting
microscope. The worms were ﬁltered using a 10 μm cell strainer
(pluriSelect), rinsed with 10 × 1 ml S-basal solution, and eluted with
1 ml S-basal solution. Around 30 xL3 worms (in S-basal solution) were
added to wells containing compound + DMSO or DMSO alone (ﬁnal
DMSO concentration 1% v/v). Worms were incubated for 2 h in the
dark at 25 °C. Movement was stimulated by illuminating the plate with
bright white light for 3 min (Zeiss HAL100), before acquiring movies on
the INVAPP/Paragon system (200 frames, 30 frames per second). The
INVAPP/Paragon movementIndexThreshold parameter was set to 2 for
analysis of H. contortus xL3, due to a lower prior expectation of worm
movement in the movie for this nematode.
2.8. Pathogen Box screening
The Pathogen Box library was obtained from the Medicines for
Malaria Venture as 10 mM solutions in DMSO, and then diluted in
DMSO to 1 mM. It was then screened in the C. elegans growth assay as
described (ﬁnal concentration 10 μM, n = 5, 1% v/v ﬁnal DMSO). Solid
material for conﬁrmatory screening of actives was obtained from
Sigma-Aldrich (tolfenpyrad) and Santa Cruz Biotechnology (auranoﬁn).
Solid samples of MMV007920, MMV020152, MMV652003 and
MMV688372 were obtained from the Medicines for Malaria Venture.
3. Results
3.1. INVAPP/Paragon: a high-throughput assay for quantifying nematode
motility and growth
We wanted to develop an assay for screening small molecules for
their eﬀect on the motility and growth of diverse parasites. A high-
throughput and automated system was particularly desirable, given the
large size of available small molecule libraries. To this end, we designed
the INVAPP/Paragon system. A schematic of the INVAPP hardware is
shown in Fig. 1A. This allows recording of movies of entire microplates
at high frame rate, reducing the per plate acquisition time to 10–30 s.
Tens of thousands of compounds or conditions can therefore be readily
screened per day.
We took a statistical approach to quantifying motility. The variance
through time for each pixel in the plate was calculated and the dis-
tribution of the variances examined. Pixels whose variance is greater
than a threshold of the mean plus typically one standard deviation are
determined to be “motile” (Fig. 1B). For organisms that are particularly
small or have limited motility, such as H. contortus L3s, this threshold
was increased to the mean plus two standard deviations, reﬂecting a
lower prior expectation of worm movement in the movie. A similar
approach was recently reported for the determination of H. contortus
motility (Preston et al., 2015). An example of this thresholding model is
shown in Fig. 1C, which shows analysis of a 96-well plate containing
uniformly-treated, adult, wild-type C. elegans. Dark pixels are those that
have been determined to be motile. Once the motility threshold has
been applied to the data, ‘motile’ pixels are assigned by well to their
plate location and counted. All analysis is fully automated via a set of
MATLAB scripts, available at https://github.com/fpartridge/invapp-
paragon (Partridge et al., 2017a).
This approach was able to quantify motility. To illustrate this, we
analysed plates containing a variable number of synchronised adult C.
elegans worms. As expected, quantiﬁed movement increased with the
number of worms per well, reﬂecting a larger number of ‘motile’ pixels
in the recording (Fig. 1D).
The system was also able to quantify nematode growth. To test this,
we synchronised C. elegans at the L1 stage, before refeeding them in
plates at two temperatures commonly used in C. elegans culture (20 °C
and 25 °C). Plates were then analysed using INVAPP/Paragon every
24 h. The results are shown in Fig. 1E. The quantiﬁed movement index
increases as worms develop from L1 to adult stage. The drop in motility
in the 25 °C group on day 5 reﬂects growth of L1 progeny leading to
exhaustion of the bacterial food source and starvation.
When establishing a high-throughput assay it is important to
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consider the issue of edge eﬀects (Malo et al., 2006). Systematic biases
across the plate are particularly common around edges. Typical causes
are evaporation, which is often worse at the edges, or temperature in-
homogeneity. In our assay, given that it involves imaging of whole
plates, we also wanted to exclude the possibility of systemic bias caused
by optical distortion. To address these concerns, we analysed a 1920-
well C. elegans growth dataset. This was chosen because the long four-
day incubation time gave the maximum possibility of confounding
evaporation diﬀerences. We classiﬁed wells on the outer rows and
columns of the plate as being outer wells, and compared their quanti-
ﬁed motility to the inner wells (Fig. 1F). There was no signiﬁcant dif-
ference between these groups (Mann-Whitney-Wilcoxon test,
P = 0.77), and therefore no evidence of problematic edge eﬀects in this
assay. To further exclude the possibility of assay inhomogeneity across
the plate, we calculated a heat map showing average normalised mo-
tility for each well (Fig. 1G). Again, this showed no evidence of sys-
temic bias by plate position.
3.2. Validation of the INVAPP/Paragon assay using existing commercial
anthelmintic standards
Having set up this high-throughput motility and growth assay, we
wanted to validate its utility by examining the eﬀects of a panel of
known anthelmintics. We selected nine anthelmintics with a variety of
reported mechanisms of action. Piperazine is a GABA agonist that acts
at the neuromuscular junction (Martin, 1985). Diethylcarbamazine has
been proposed to have a similar mechanism, although other mechan-
isms including targeting host arachidonic acid metabolism are also
thought to be important (Maizels and Denham, 1992). Levamisole,
oxantel and pyrantel are nicotinic acetylcholine receptor agonists that
induce spastic paralysis (Martin et al., 1997). Mebendazole is an in-
hibitor of beta-tubulin polymerisation (Driscoll et al., 1989). Ivermectin
is a positive allosteric modulator of glutamate-gated chloride channels
although other targets have also been suggested (Cully et al., 1994).
Trichlorfon is a member of the organophosphate group of acetylcholine
esterase inhibitors. Praziquantel is thought to act by disrupting calcium
ion homeostasis but its target is unclear (Caﬀrey, 2007).
Fig. 1. The INVAPP /Paragon movement index algorithm is a fully-automated high-throughput system able to determine motility and growth rate. (A) Schematic of the INVAPP
setup (B) Principle of the algorithm: thresholding of moving pixels by statistical analysis of variance of each pixel through time. Histogram shows the distribution of pixel variance over
time. Data was from obtained from a movie of all wells in a single 96-well plate containing wild-type C. elegans. The distribution is obtained by counting the number of pixels that fall into
each bin of log pixel variance over time. Blue vertical line indicates mean pixel variance. The green vertical line indicates mean plus standard deviation of pixel variance; the blue shaded
portion of the histogram indicates pixels that exceed this threshold so are deemed to be ‘motile’. (C) Image of 96-well plate containing C. elegans adults processed by the INVAPP/Paragon
movement index system. Dark pixels are those categorized as moving by the algorithm. (D) Increasing the number of C. elegans worms per well leads to increase in reported movement
index. Boxplot bars indicate 95% conﬁdence interval. Dataset contains 16 wells per group from a single 96-well plate. (E) Movement index algorithm is able to quantify C. elegans growth
in 96-well plates. Movement index increases with growth. Synchronised L1 population refed on day 0. Decrease in movement index in 25 °C group on Day 4 reﬂects completion of the C.
elegans lifecycle and exhaustion of the bacterial food source. Boxplot notches indicate 95% conﬁdence interval, n = 192 wells of worms for each of the 20 °C and 25 °C groups. (F) Absence
of edge eﬀects in this assay – analysis of a 1920-well C. elegans growth dataset shows no diﬀerence of the normalised movement score for 96-well plate outer edge wells (the wells found in
columns 1 and 12 or rows A and H) compared to the score for inner wells (the other wells in the plate). Dataset is from a total of 20 96-well plate movies obtained from C. elegans grown at
20 °C, 25 °C and 26 °C to show that this assay is robust over a range of experimentally useful temperatures. Movement index for each well is normalised by dividing by the mean
movement index for all wells of that plate. The blue bar indicates median. (G) No edge eﬀects or other inhomogeneity across the plate – heat map shows average normalised movement
index for each well location. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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We ﬁrst measured concentration-response curves for this panel of
anthelmintics in an acute treatment (3 h) adult C. elegans assay. The
results are shown in Fig. 2. As expected, the major ion channel-tar-
geting drugs ivermectin, levamisole, oxantel and pyrantel were active
in this assay, reﬂecting their direct eﬀects on worm motility.
We then measured concentration-response curves for this panel of
anthelmintics in a chronic treatment C. elegans growth assay (5 days,
20 °C, from L1 stage). The results are shown in Fig. 3. Activity was again
found with ivermectin, levamisole, oxantel and pyrantel and, ad-
ditionally, with mebendazole, piperazine and trichlorfon. This reﬂects
that some anthelmintic modes of action may not be measured in purely
acute motility assays (at least for shorter-lived nematodes such as C.
elegans), supporting the use of assays that involve growth or develop-
ment. Indeed, an action of macrocyclic lactones distinct from that on
motility has been proposed (Wolstenholme et al., 2016). Diethylcar-
bamazine and praziquantel were not active in these assays as expected.
This reﬂects previously reported low in vitro activity of diethylcarba-
mazine and its proposed mechanism of acting on host arachidonic acid
metabolism (Maizels and Denham, 1992). Praziquantel, used primarily
to treat ﬂukes and tapeworms, is known to have limited eﬃcacy against
nematodes (Holden-Dye, 2007). Successfully demonstrating the ability
of the INVAPP/Paragon system to determine the eﬀects of known an-
thelmintics increased our conﬁdence in this approach.
3.3. Adaptation of the INVAPP/Paragon assay to parasitic nematodes
C. elegans is a useful model because of the ease of laboratory culture
and access to powerful genetic tools. However, it is also valuable to
screen parasitic nematodes directly. T. circumcincta is a globally
important parasitic nematode that infects small ruminants. We tested
the ability of the INVAPP/Paragon system to quantify the activity of the
anthelmintic ivermectin on ensheathed T. circumcincta L3. Worms were
incubated at 25 °C with the compounds for 2 h in the dark, after which
movement was induced by bright light and movies recorded on the
INVAPP system. Fig. 4A shows an example of the INVAPP/Paragon
motility thresholding of single wells treated with DMSO or DMSO plus
100 μM ivermectin, showing much reduced, but not abolished move-
ment, of these larvae in the assay. We obtained a concentration-re-
sponse curve for ivermectin (Fig. 4B), demonstrating the ability of the
system to quantify motility of this parasite.
H. contortus, the barber's pole worm, is another economically im-
portant gastrointestinal parasite of small ruminants. We tested the
ability of the INVAPP/Paragon system to quantify the activity of iver-
mectin on exsheathed L3 (xL3) H. contortus. Worms were incubated at
25 °C with the compounds for 2 h in the dark, after which movement
was induced by bright light and movies recorded on the INVAPP
system. An example of the INVAPP/Paragon motility thresholding of
single wells treated with DMSO or a DMSO solution of ivermectin
(assay concentration 100 μM) is shown in Fig. 5A. Movement of iver-
mectin-treated xL3s in the assay was considerably reduced. A con-
centration-response curve for ivermectin is shown in Fig. 5B, illus-
trating the ability of the system to quantify motility of this parasite. A
caveat to these results, regarding their potential translation to in vivo
potency, is that under physiological conditions H. contortus becomes
exsheathed in the stomach at 38–41 °C. Therefore activity in this assay
at 25 °C may not fully reﬂect the in vivo action of ivermectin.
Trichuris muris, which infects mice, is a widely used laboratory
model for investigating trichuriasis and has been used as a system for ex
Fig. 2. Determination of the eﬀect of acute
treatment (3 h) with important anthelmintics
on C. elegans adult motility using the INVAPP/
Paragon movement index algorithm. Blue line
ﬁtted using the 3-parameter log-logistic model.
EC50 values are shown in parentheses, with stan-
dard error for this estimate calculated using drc
(Ritz and Streibig, 2005). Each dot indicates
movement score for one well. n = 5 wells for
each concentration, with each replicate con-
centration on diﬀerent plates. (For interpretation
of the references to color in this ﬁgure legend, the
reader is referred to the Web version of this ar-
ticle.)
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vivo and in vivo testing of anthelmintic candidates for activity against
whipworm (Hurst et al., 2014; Tritten et al., 2011; Wimmersberger
et al., 2013). We tested the ability of the INVAPP/Paragon system to
quantify the activity of the anthelmintic levamisole on adult T. muris.
Worms were incubated at 37 °C with the compounds for 24 h in the
dark, after which movement was recorded on the INVAPP system.
Fig. 6A shows control and levamisole treated wells. For illustration,
selected frames of the movie are shown (3 second intervals). The
readout of ‘motile’ pixels as determined by the INVAPP/Paragon algo-
rithm is shown in Fig. 6B, showing the quantiﬁcation of the loss of
Fig. 3. Determination of the eﬀect of important anthelmintics on C. elegans growth using the INVAPP/Paragon movement index algorithm. Chronic treatment for 5 days from L1
stage. Blue line ﬁtted using the 3-parameter log-logistic model. EC50 values are shown in parentheses, with standard error for this estimate calculated using drc (Ritz and Streibig, 2005).
Each dot indicates movement score for one well. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
Fig. 4. Utilising the INVAPP/Paragon system with ensheathed L3 T. circumcincta. (A) INVAPP/Paragon motility thresholding of single wells treated with DMSO or a DMSO solution
of ivermectin (assay concentration 100 μM). Black pixels show those scored as being ‘motile’ by the software. (B) Concentration-response curve for treatment with the anthelmintic
ivermectin, n = 4. Each replicate was carried out in diﬀerent experimental sessions, using one batch of L3 T. circumcincta. Curve ﬁtted using the four-parameter log-logistic function. Error
range on the EC50 estimate indicates standard error (delta method).
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motility of the levamisole-treated worm. A concentration-response
curve for levamisole was measured (Fig. 6C), which illustrates the
ability of the system to quantify motility of this parasite and thus
measure anthelmintic activity.
3.4. Screening the Pathogen Box for compounds that aﬀect C. elegans
growth
We then applied the INVAPP/Paragon assay system to the identiﬁ-
cation of novel anthelmintic small molecules. We used the Pathogen
Box, a collection of 400 diverse drug-like molecules that are known to
be active against various neglected disease pathogens (particularly,
tuberculosis (or Mycobacterium spp.), malaria and kinetoplastid pro-
tozoa). This library is distributed as an open-science project by the
Medicines for Malaria Venture. A screen of this library for compounds
aﬀecting motility of exsheathed L3 of H. contortus has been published
recently (Preston et al., 2016b), which identiﬁed the insecticide, tol-
fenpyrad, as active against the larvae. To complement this approach,
and with the aim of identifying compounds blocking growth of nema-
todes as opposed to solely immobilising them, we screened the library
in a blinded fashion (5 separate library plate sets in total, using worms
from 2 separately prepared batches of C. elegans L1 larvae, experiment
conducted on 2 diﬀerent occasions, ﬁnal compound concentration
10 μM) using the INVAPP/Paragon C. elegans growth assay. For each
compound, motility change and signiﬁcance (Mann-Whitney-Wilcoxon
test) were calculated relative to DMSO-only control wells. A volcano
plot showing the results of this screen is shown in Fig. 7A. Compounds
that reproducibly reduced growth are found towards the top left of this
plot. To conﬁrm identity of the hit molecules, we retested the top 20
putative hit compounds in a secondary screen with the same library
material (n = 5, concentration 10 μM) in the same INVAPP/Paragon C.
elegans growth assay (Fig. 7B). A total of 18 out of 20 compounds were
active (P < 0.05, Dunnett's multiple comparison test).
The combined assay results from the primary and secondary screen
are found in Supplementary File 1 and have been recorded in the
PubChem database with Assay ID 1259336.
3.5. Identiﬁcation of known anthelmintic compounds by screening the
Pathogen Box in the C. elegans growth assay
We ﬁrst considered known anthelmintic compounds that we found
to be active in this screen (Table 1). Mebendazole, an anthelmintic from
the benzimidazole group, acts by inhibiting microtubule synthesis
(Laclette et al., 1980). Tolfenpyrad is a broad-spectrum acaricide and
insecticide that acts as an inhibitor of complex I of the electron trans-
port chain (Yu, 2014). It has been recently reported to reduce motility
of H. contortus exsheathed L3 and to block L3 to L4 development of this
parasite in vitro (Preston et al., 2016b). We conﬁrmed activity of this
compound using solid material. As shown in Fig. 7C, the EC50 was
200 ± 40 nM. Independently identifying these known anthelmintic
compounds using a blinded screening approach further validates the
INVAPP/Paragon system as a robust high throughput screening ap-
proach.
Auranoﬁn is a gold(I) compound originally developed for the
treatment of rheumatoid arthritis. It has received attention for re-
purposing as an anti-cancer agent, with a number of clinical trials under
way. It has been shown that auranoﬁn has in vitro and in vivo activity in
several models of parasitic diseases, including schistosomiasis (Kuntz
Fig. 5. Utilising the INVAPP/Paragon system with exsheathed L3 H. contortus. (A) INVAPP/Paragon motility thresholding of single wells treated with DMSO or a DMSO solution of
ivermectin (assay concentration 100 μM). Black pixels show those scored as being ‘motile’ by the software. (B) Concentration-response curve for treatment with the anthelmintic
ivermectin, n = 4. Each replicate drug treatment was carried out in diﬀerent experimental sessions, each time freshly exsheathing the worms by bleach treatment, using one batch of
ensheathed L3 H. contortus. Curve ﬁtted using the four-parameter log-logistic function. Error range on the EC50 estimate indicates standard error (delta method).
Fig. 6. Utilising the INVAPP/Paragon system with adult
T. muris. (A) Example of section of movie, showing control
and levamisole-treated wells. Selected movie frames are
shown at 3-s intervals (B) Pixels for these wells that are
considered to be motile as determined by the algorithm are
shown in red. (C) Concentration-response curves for treat-
ment with the anthelmintic levamisole, n = 4 wells per
concentration, each replicate well on diﬀerent plates using
independent batches of T. muris from diﬀerent mice, over 2
experimental sessions. Curve ﬁtted using the three-para-
meter log-logistic function. Error range on the EC50 estimate
indicates standard error (delta method). (For interpretation
of the references to color in this ﬁgure legend, the reader is
referred to the Web version of this article.)
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et al., 2007), amoebiasis (Debnath et al., 2012), leishmaniasis (Sharlow
et al., 2014) and onchocerciasis (Bulman et al., 2015). A phase IIa trial
of auranoﬁn for gastrointestinal protozoal infection is ongoing. We
conﬁrmed activity of this compound in the C. elegans growth assay
using solid material. As shown in Fig. 7D, the EC50 of this compound
was 1.1 ± 0.3 μM.
Isradipine is an antihypertensive drug that belongs to the dihy-
dropyridine family of L-type calcium channel blockers. A structurally
related dihydropyridine, nemadipine-A, has been shown to cause
growth and egg laying defects in C. elegans by antagonising the L-type
calcium channel α1-subunit EGL-19 (Kwok et al., 2006). We conﬁrmed
activity of this compound in the C. elegans growth assay using solid
material. As shown in Fig. 7E, the EC50 of this compound was
1.6 ± 0.7 μM.
3.6. Assessment of screen performance
The pathogen box screen was screened blindly without the addition
Fig. 7. Screening the Pathogen Box in the C.
elegans growth screen. (A) Volcano plot showing
the results of the primary screen (n = 5 replicates
per compound, concentration = 10 μM, each re-
plicate was on diﬀerent plates, over two experi-
mental sessions). Each point represents one com-
pound. Eﬀective size is shown on the x axis, as
log2-fold change (ratio of the median movement
for the repeats of the compound to the median
movement of DMSO-only wells). Statistical sig-
niﬁcance is shown on the y axis as the -log10 P
value in the Mann-Whitney-Wilcoxon test. A lo-
cation at the top left of this plot indicates an-
thelmintic activity. (B) Secondary rescreen of hit
compounds, using library material, in order of
their activity in the primary screen. Statistical
signiﬁcance compared to DMSO-only control cal-
culated by Dunnett's multiple comparison test
(n = 5, * indicates P < 0.05, ** indicates
P < 0.005, **** indicates P < 0.0005). (C,D,E)
Concentration-response curves showing the ac-
tivity of known anthelmintics – (C) tolfenpyrad,
(D) auranoﬁn, (E) isradipine – that were found in
the Pathogen box screen retested using solid ma-
terial (supplied by the Medicines for Malaria
Venture) in the C. elegans growth assay. A con-
centration-response curve for mebendazole in the
assay was presented in Fig. 3. Error bars indicate
standard deviation, n = 4 wells per concentration
per compound. Curve ﬁtting was undertaken
using three parameter log logistic model
(Graphpad Prism).
Table 1
Named compounds that were active in the C. elegans growth screen. Log2-fold change in growth estimate compared to DMSO-only controls. Hit ID is as in Fig. 7B. EC50 conﬁdence
interval is the standard error. The EC50 estimate for mebendazole is from Fig. 3. Primary and secondary screens used solutions supplied as part of the Pathogen Box Library. EC50 estimates
were determined using solid material.
Compound MMV ID PubChem CID Hit ID Log2 fold change in growth EC50 (μM) ± standard error
(1° screen) (2° screen) (solid material)
Tolfenpyrad MMV688934 10,110,536 1 −10.9 −10.6 0.2 ± 0.04
Auranoﬁn MMV688978 24,199,313 2 −10.9 −7.2 1.1 ± 0.3
Mebendazole MMV003152 4030 5 −6.0 −5.7 1.1 ± 0.2
Isradipine MMV001493 158,617 16 −2.2 −1.4 1.6 ± 0.7
Tavaborole n/a 11,499,245 n/a n/a 8.6 ± 1.9
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of positive control compounds. However we wanted to assess the per-
formance of the screen. We therefore treated wells containing me-
bendazole as positive controls for comparison against negative control
DMSO-only wells. We then calculated the strictly standardized mean
diﬀerence (SSMD) parameter, which is a principled statistical assess-
ment of high-throughput screen performance (Birmingham et al., 2009;
Zhang et al., 2007; Zhang, 2011). For the positive control mebendazole
we calculated that SSMD β = −2.54. This indicates that screen per-
formance was adequate to good (for a strong control−3 < β < −2 is
considered good).
3.7. Novel anthelmintics that block C. elegans growth
Fourteen compounds without previously-described anthelmintic
activity were identiﬁed in the Pathogen Box screen (Table 2). The
structures of the most active compounds are shown in Fig. 8. We ex-
amined four of these compounds more closely. First, we determined
activity, using solid material, in the C. elegans growth assay (Fig. 9). The
EC50 values for the conﬁrmatory assay are shown in Table 2. These
results have been recorded in the PubChem database with Assay ID
1259335.
MMV007920 is a benzoxazole-containing compound previously
identiﬁed in a screen for agents that inhibit Plasmodium falciparum
proliferation. The target of this compound is not known but it has been
suggested that some benzoxazole compounds act on beta-tubulin
(Satyendra et al., 2011). MMV020152 is an isoxazole-containing com-
pound previously identiﬁed in a screen for compounds that inhibit P.
falciparum growth. A number of other compounds also containing iso-
xazole motifs have been shown to have insecticidal activity (da Silva-
Alves et al., 2013). MMV688372 is an imidazopyridine-containing
compound that has been previously shown to have in vivo anti-trypa-
nosomal activity (Tatipaka et al., 2014).
MMV652003 is a benzoxaborole-containing compound that has also
been given the identiﬁer AN3520 in the literature. This compound has
potent activity against Trypanosoma sp., both in vitro, and in murine
models of human African trypanosomiasis (Nare et al., 2010). In this
context this compound has been iteratively improved leading to the
identiﬁcation of the close relative SCYX-7158 (Jacobs et al., 2011),
which is currently in clinical trials. The anti-trypanosomal target of this
benzoxaborole class is not known (Jones et al., 2015). A simpler
benzoxaborole compound, tavaborole (Fig. 10B), has been approved as
an anti-fungal (Elewski et al., 2015). This acts by inhibiting cytoplasmic
leucyl-tRNA synthetase by forming an adduct with tRNALeu in the en-
zyme editing site (Rock et al., 2007). Benzoxaborole anthelmintic
agents are being developed by Anacor/Eli Lilly (Akama et al., 2014;
Zhang et al., 2011). Benzoxaborole compounds also show promise for
other infectious diseases, including malaria, cryptosporidiosis, tox-
oplasmosis and tuberculosis, in each case acting via inhibition of leucyl-
tRNA synthetase (Palencia et al., 2016a, 2016b; Sonoiki et al., 2016).
Given the eﬀect of MMV652003 and the similarity of this compound
to the already approved drug tavaborole, we determined whether ta-
vaborole was eﬀective in the C. elegans growth assay. Tavaborole
showed concentration-dependent growth inhibition (Fig. 10C) with an
EC50 of 8.6 ± 1.9 μM (Table 1). This is similar to that of the ben-
zoxaborole screen hit, MMV652003, which has an EC50 of
4.3 ± 2.5 μM (Table 1). These results support the development of a
benzoxaborole anti-nematode agent.
4. Discussion
There is an urgent need for new anthelmintics. Despite encouraging
progress with MDA programs, current strategies and therapies will not
achieve eradication of, for example, T. trichiura (Keiser and Utzinger,
2008; Turner et al., 2016). Furthermore, MDA, particularly with drugs
that do not fully clear infection, may lead to drug resistance (Vercruysse
et al., 2011). The experience from veterinary parasitology is that re-
sistance to new anthelmintics can develop relatively rapidly after re-
gistration, causing major economic impacts and risks to global food
security (Sales and Love, 2016; Scott et al., 2013).
In this manuscript, we present the INVAPP/Paragon system which,
based on imaging of whole microplates and thresholding pixel variance
to determine motion, is able to quantify growth and/or motility of
parasitic nematodes and the free-living nematode, C. elegans. A strength
of this system is its high-throughput capability, typically imaging a
whole plate for 5–20 s is suﬃcient to reliably quantify motion in all 96
wells. We demonstrated this eﬀect by determining eﬃcacy of a panel of
anthelmintics in both acute motility and growth assays in C. elegans and
of known anthelmintics in H. contortus, T. circumcincta, and T. muris
assays. We further demonstrated utility of the system in a screen of
small molecules for compounds that block or limit C. elegans growth.
Current anthelmintic screens generally focus on motility reduction, as
growth of parasitic nematodes can be diﬃcult to model in vitro, with
larvae failing to moult through their larval stages outside of the host.
However anthelmintic activity in vivo can be much broader than in-
hibition of motility and thus screening compounds for their ability to
inhibit C. elegans growth, rather than motility, represents a useful
strategy to identify compounds which can subsequently be tested for
growth inhibition activity in vivo. We used the Pathogen Box, a library
of a collection of 400 diverse drug-like molecules known to be active
against various neglected diseases, distributed as an open-science pro-
ject by the Medicines for Malaria Venture.
Identifying the compounds with known anthelmintic or anti-para-
sitic activity mebendazole and tolfenpyrad (Preston et al., 2016b) using
independent blinded screening approach serves as an important vali-
dation and supports the robustness of the screening platform. Re-
purposing of existing drugs for new indications is an established ap-
proach in drug discovery (Zheng et al., 2017) and is particularly
valuable for neglected tropical diseases as it may reduce research and
development costs and speed progress to clinical trials (Pollastri and
Campbell, 2011). Auranoﬁn has recently been shown to have activity
against ﬁlarial nematode infection (Bulman et al., 2015). Our identiﬁ-
cation of auranoﬁn as a compound that blocks C. elegans growth lends
support to test repurposing of this compound for nematode infections.
Isradipine, a safe and well-tolerated L-type calcium channel blocker,
was also active in the screen. Assaying the activity of isradipine in in
vivo models of parasitic infection is a priority and could lead to
Table 2
Compounds with previously unreported anthelmintic activity that were active in
the C. elegans growth screen. MMV ID is the compound identiﬁer for the Medicines for
Malaria Venture. PubChem CID is the compound identiﬁer for the PubChem database. Hit
ID is as in Fig. 7B. Log2 fold change in the growth estimate in the INVAPP/Paragon assay
compared to DMSO-only controls. Primary and secondary screens used solutions supplied
as part of the Pathogen Box Library. EC50 estimates were determined using solid material,
supplied by the Medicines for Malaria Venture.








MMV652003 46,196,110 3 −8.9 −7.6 4.3 ± 2.5
MMV007920 721,133 4 −7.0 −5.4 6.2 ± 2.4
MMV688372 72,710,598 6 −5.8 −4.0 3.3 ± 1.7
MMV675994 44,222,802 7 −5.7 −2.0 n.d.
MMV026550 44,530,521 8 −5.5 −5.9 n.d.
MMV020391 7,918,647 9 −5.0 −2.7 n.d.
MMV676395 54,678,166 10 −4.8 −4.8 n.d.
MMV020152 8,880,740 12 −3.1 −6.9 2.5 ± 1.0
MMV676406 30,238,526 14 −2.7 −8.0 n.d.
MMV688417 58,346,931 15 −2.6 −1.1 n.d.
MMV688936 18,589,797 17 −2.2 −3.7 n.d.
MMV1028806 16,387,386 18 −2.1 −0.8 n.d.
MMV688888 5,179,236 19 −2.0 −2.1 n.d.
MMV687180 41,058,173 20 −1.8 −3.6 n.d.
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repurposing trials.
We also identiﬁed 14 compounds with previously undescribed an-
thelmintic activity in the C. elegans growth assay, belonging to a variety
of chemical classes. These include benzoxazole and isoxazole com-
pounds previously shown to have activity against P. falciparum (da
Silva-Alves et al., 2013; Satyendra et al., 2011), and an imidazopyr-
idine-containing compound previously shown to have in vivo anti-try-
panosomal activity (Tatipaka et al., 2014). Another notable active
compound was the benzoxaborole, MMV652003. Since the
identiﬁcation and successful progression into the clinic of the anti-
fungal tavaborole, a number of benzoxaborole compounds have been
reported to show potential for trypanosomiasis, malaria, cryptospor-
idiosis, toxoplasmosis and tuberculosis (Liu et al., 2014). These results
support the idea that some drug chemotypes can have activity against a
diversity of infectious agents. Given the costs of drug development and
the limited resources available for the discovery of new drugs targeting
neglected tropical diseases, it seems possible that an open source
medicinal chemistry program could catalyse discovery for many
Fig. 8. Structures of the most active compounds, previously
undescribed as anthelmintics, which were found to have ac-
tivity in the C. elegans growth screen. Compound numbers from
Medicines for Malaria Venture Pathogen Box.
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diﬀerent indications (Van Voorhis et al., 2016). Whilst preparing this
manuscript we have applied the INVAPP/Paragon system to library-
scale screening measuring motility of ex vivo T. muris adults, which led
to identiﬁcation of a new class of anthelmintics, the dihydrobenzox-
azepinones (Partridge et al., 2017b). Taken together these results de-
monstrate the potential for anthelmintic discovery using this system,
with new compounds with anthelmintic activity identiﬁed by screens
using both the free-living nematode C. elegans as a parasite model, and
the mouse whipworm T. muris.
The anthelmintic compounds we have identiﬁed in this study were
active in a growth assay using C. elegans, which is typically considered a
free-living nematode, although it undoubtedly has utility in anthel-
mintic drug discovery (Burns et al., 2015). A critical step to support the
development of these compounds will be to determine their activity on
important human and animal parasitic nematodes. These compounds
were inactive in a recently reported screen that determined their eﬀects
on motility of H. contortus xL3 (Preston et al., 2016b). It is therefore
possible that their activity requires active growth of the target nema-
tode, perhaps reﬂecting a target distinct from the neuromuscular
system. A recent set of criteria for hit-to-lead progression in neglected
infective diseases provides a useful guide to the steps that need to be
taken to progress these early-stage hit compounds (Nwaka et al., 2009).
It will be particularly important to demonstrate activity against a range
of nematode parasites and diﬀerential sensitivity between parasite and
host to support the development of a new anthelmintic.
We focused our application of the INVAPP/Paragon system to
Fig. 9. Concentration-response relationships for selected hit compounds in the C. elegans growth screen, using solid material supplied by Medicines for Malaria Venture. (A)
MMV007920 (B) MMV020152 (C) MMV652003 (D) MMV688372. N = 4 wells per concentration per compound. Curve ﬁtting was undertaken using three parameter log logistic model
(Graphpad Prism).
Fig. 10. Benzoxaborole compounds as anthelmintics. Structures of (A) the screen hit MMV652003 and (B) the related benzoxaborole tavaborole, which is approved as an anti-fungal.
(C) Concentration-response curve for tavaborole in the C. elegans growth assay. N = 5 wells per concentration. Blue line ﬁtted using three parameter log logistic model with drc (Ritz and
Streibig, 2005). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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investigating parasitic diseases. However, given its ability to determine
growth and motility of C. elegans quickly and robustly, it could also be
applied to the study of other human diseases modelled in C. elegans.
In conclusion, we have developed a high-throughput system for
measuring the growth and/or motility of parasitic and free-living ne-
matodes. Quantiﬁcation of the activity of known anthelmintics and
identiﬁcation of novel chemotypes with anthelmintic activity was de-
monstrated, validating our approach. The system is well suited to li-
brary-scale screening of chemicals with many human and animal health
applications.
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